|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM31 |
Gene summary for TRIM31 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM31 | Gene ID | 11074 |
| Gene name | tripartite motif containing 31 | |
| Gene Alias | C6orf13 | |
| Cytomap | 6p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q2L6J1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11074 | TRIM31 | S027 | Human | Liver | HCC | 3.40e-03 | 5.48e-01 | 0.2446 |
| 11074 | TRIM31 | S028 | Human | Liver | HCC | 3.28e-09 | 3.82e-01 | 0.2503 |
| 11074 | TRIM31 | S029 | Human | Liver | HCC | 1.87e-16 | 1.25e+00 | 0.2581 |
| 11074 | TRIM31 | Pat01-B | Human | Stomach | GC | 7.22e-20 | 4.57e-01 | 0.5754 |
| 11074 | TRIM31 | Pat02-B | Human | Stomach | GC | 3.69e-15 | 1.42e-01 | 0.0368 |
| 11074 | TRIM31 | Pat03-B | Human | Stomach | GC | 6.83e-11 | 2.06e-01 | 0.3693 |
| 11074 | TRIM31 | Pat04-B | Human | Stomach | GC | 6.25e-09 | 2.11e-01 | -0.1483 |
| 11074 | TRIM31 | Pat06-B | Human | Stomach | GC | 4.82e-28 | 3.76e-01 | -0.1961 |
| 11074 | TRIM31 | Pat09-B | Human | Stomach | GC | 4.68e-08 | 3.52e-01 | -0.0359 |
| 11074 | TRIM31 | Pat10-B | Human | Stomach | GC | 3.82e-07 | 6.12e-01 | 0.084 |
| 11074 | TRIM31 | Pat11-B | Human | Stomach | GC | 7.69e-03 | 1.53e-01 | -0.182 |
| 11074 | TRIM31 | Pat15-B | Human | Stomach | GC | 2.07e-05 | 2.68e-01 | -0.0778 |
| 11074 | TRIM31 | Pat16-B | Human | Stomach | GC | 1.97e-25 | 6.57e-01 | 0.1918 |
| 11074 | TRIM31 | Pat17-B | Human | Stomach | GC | 1.10e-25 | 7.43e-01 | 0.3109 |
| 11074 | TRIM31 | Pat18-B | Human | Stomach | GC | 1.15e-05 | 2.38e-01 | -0.0432 |
| 11074 | TRIM31 | Pat19-B | Human | Stomach | GC | 7.09e-09 | 3.01e-01 | 0.0826 |
| 11074 | TRIM31 | Pat22-B | Human | Stomach | GC | 4.26e-21 | 3.03e-01 | -0.1042 |
| 11074 | TRIM31 | Pat24-B | Human | Stomach | GC | 9.53e-07 | 2.70e-01 | -0.1184 |
| 11074 | TRIM31 | Pat25-A | Human | Stomach | CAG with IM | 1.50e-04 | 4.17e-02 | -0.1648 |
| 11074 | TRIM31 | Pat26-A | Human | Stomach | CSG | 1.34e-16 | 2.51e-01 | -0.2402 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0044403 | Colorectum | AD | biological process involved in symbiotic interaction | 99/3918 | 290/18723 | 1.02e-07 | 4.93e-06 | 99 |
| GO:0019080 | Colorectum | AD | viral gene expression | 42/3918 | 94/18723 | 1.90e-07 | 8.02e-06 | 42 |
| GO:0051701 | Colorectum | AD | biological process involved in interaction with host | 73/3918 | 203/18723 | 5.08e-07 | 1.88e-05 | 73 |
| GO:0052126 | Colorectum | AD | movement in host environment | 63/3918 | 175/18723 | 2.85e-06 | 8.11e-05 | 63 |
| GO:0050792 | Colorectum | AD | regulation of viral process | 59/3918 | 164/18723 | 5.95e-06 | 1.52e-04 | 59 |
| GO:0046718 | Colorectum | AD | viral entry into host cell | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
| GO:1903900 | Colorectum | AD | regulation of viral life cycle | 51/3918 | 148/18723 | 9.01e-05 | 1.38e-03 | 51 |
| GO:0044409 | Colorectum | AD | entry into host | 51/3918 | 151/18723 | 1.60e-04 | 2.21e-03 | 51 |
| GO:0019076 | Colorectum | AD | viral release from host cell | 15/3918 | 34/18723 | 1.96e-03 | 1.58e-02 | 15 |
| GO:0035890 | Colorectum | AD | exit from host | 15/3918 | 34/18723 | 1.96e-03 | 1.58e-02 | 15 |
| GO:0035891 | Colorectum | AD | exit from host cell | 15/3918 | 34/18723 | 1.96e-03 | 1.58e-02 | 15 |
| GO:0051091 | Colorectum | AD | positive regulation of DNA-binding transcription factor activity | 73/3918 | 260/18723 | 3.52e-03 | 2.54e-02 | 73 |
| GO:00160321 | Colorectum | SER | viral process | 118/2897 | 415/18723 | 8.36e-12 | 1.65e-09 | 118 |
| GO:00190581 | Colorectum | SER | viral life cycle | 87/2897 | 317/18723 | 2.82e-08 | 1.94e-06 | 87 |
| GO:00517011 | Colorectum | SER | biological process involved in interaction with host | 55/2897 | 203/18723 | 1.42e-05 | 4.38e-04 | 55 |
| GO:00444031 | Colorectum | SER | biological process involved in symbiotic interaction | 72/2897 | 290/18723 | 2.08e-05 | 6.02e-04 | 72 |
| GO:00521261 | Colorectum | SER | movement in host environment | 47/2897 | 175/18723 | 7.30e-05 | 1.64e-03 | 47 |
| GO:00190801 | Colorectum | SER | viral gene expression | 29/2897 | 94/18723 | 1.32e-04 | 2.66e-03 | 29 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM31 | insertion | Frame_Shift_Ins | novel | c.98_99insAGCTCTACAAGCCTCTGAGGTGCAGTCCAAAAGGAAAGAGGCTACATGCC | p.His33GlnfsTer45 | p.H33Qfs*45 | Q9BZY9 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| TRIM31 | SNV | Missense_Mutation | c.126G>C | p.Gln42His | p.Q42H | Q9BZY9 | protein_coding | deleterious(0.01) | probably_damaging(0.95) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TRIM31 | SNV | Missense_Mutation | novel | c.824N>G | p.Lys275Arg | p.K275R | Q9BZY9 | protein_coding | deleterious(0.02) | benign(0.122) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| TRIM31 | SNV | Missense_Mutation | c.254N>C | p.Glu85Ala | p.E85A | Q9BZY9 | protein_coding | deleterious(0.01) | benign(0.024) | TCGA-AA-3952-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| TRIM31 | SNV | Missense_Mutation | c.1163C>T | p.Ala388Val | p.A388V | Q9BZY9 | protein_coding | deleterious_low_confidence(0.02) | benign(0.038) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TRIM31 | SNV | Missense_Mutation | c.134N>G | p.Glu45Gly | p.E45G | Q9BZY9 | protein_coding | tolerated(0.08) | benign(0.18) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRIM31 | SNV | Missense_Mutation | novel | c.722N>A | p.Met241Lys | p.M241K | Q9BZY9 | protein_coding | deleterious(0.01) | benign(0.017) | TCGA-AG-A032-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | bevacizumab | PD |
| TRIM31 | SNV | Missense_Mutation | rs201488158 | c.61N>A | p.Asp21Asn | p.D21N | Q9BZY9 | protein_coding | deleterious(0) | possibly_damaging(0.574) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TRIM31 | SNV | Missense_Mutation | novel | c.1270T>C | p.Ser424Pro | p.S424P | Q9BZY9 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| TRIM31 | SNV | Missense_Mutation | c.539N>T | p.Arg180Met | p.R180M | Q9BZY9 | protein_coding | tolerated(0.09) | benign(0.269) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |